<table id="_RefID0EIDAG" width="100%" xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<caption>Table 3: Active Metabolite Pharmacokinetics and Antiplatelet Responses by CYP2C19 Metabolizer Status</caption>
<col width="23%"></col>
<col width="18%"></col>
<col width="16%"></col>
<col width="15%"></col>
<col width="15%"></col>
<col width="13%"></col>
<tbody>
<tr>
<td stylecode="Botrule Lrule Toprule " valign="top">
<paragraph> <br/>
</paragraph>
</td>
<td stylecode="Botrule Toprule " valign="top">
<paragraph> Dose <br/>
</paragraph>
</td>
<td align="center" stylecode="Botrule Toprule " valign="top">
<paragraph> Ultrarapid<br/>(n=10)<br/>
</paragraph>
</td>
<td align="center" stylecode="Botrule Toprule " valign="top">
<paragraph> Extensive<br/>(n=10)<br/>
</paragraph>
</td>
<td align="center" stylecode="Botrule Toprule " valign="top">
<paragraph> Intermediate<br/>(n=10)<br/>
</paragraph>
</td>
<td align="center" stylecode="Rrule Botrule Toprule " valign="top">
<paragraph> Poor<br/>(n=10)<br/>
</paragraph>
</td>
</tr>
<tr>
<td stylecode="Lrule " valign="top">
<paragraph> Cmax (ng/mL) <br/>
</paragraph>
</td>
<td valign="top">
<paragraph> 300 mg (24 h)<br/>600 mg (24 h) <br/>75 mg (Day 5) <br/>150 mg (Day 5) <br/>
<br/>
</paragraph>
</td>
<td align="center" valign="top">
<paragraph> 24 (10)<br/>36 (13)<br/>12 (6)<br/>16 (9)<br/>
</paragraph>
</td>
<td align="center" valign="top">
<paragraph> 32 (21)<br/>44 (27)<br/>13 (7)<br/>19 (5)<br/>
</paragraph>
</td>
<td align="center" valign="top">
<paragraph> 23 (11)<br/>39 (23)<br/>12 (5)<br/>18 (7)<br/>
</paragraph>
</td>
<td align="center" stylecode="Rrule " valign="top">
<paragraph> 11 (4)<br/>17 (6)<br/>4 (1)<br/>7 (2)<br/>
</paragraph>
</td>
</tr>
<tr>
<td stylecode="Lrule " valign="top">
<paragraph> IPA (%)* <br/>
</paragraph>
</td>
<td valign="top">
<paragraph> 300 mg (24 h)<br/>600 mg (24 h) <br/>75 mg (Day 5) <br/>150 mg (Day 5) <br/>
<br/>
</paragraph>
</td>
<td align="center" valign="top">
<paragraph> 40 (21)<br/>51 (28)<br/>56 (13)<br/>68 (18)<br/>
</paragraph>
</td>
<td align="center" valign="top">
<paragraph> 39 (28)<br/>49 (23)<br/>58 (19)<br/>73 (9)<br/>
</paragraph>
</td>
<td align="center" valign="top">
<paragraph> 37 (21)<br/>56 (22)<br/>60 (18)<br/>74 (14)<br/>
</paragraph>
</td>
<td align="center" stylecode="Rrule " valign="top">
<paragraph> 24 (26)<br/>32 (25)<br/>37 (23)<br/>61 (14)<br/>
</paragraph>
</td>
</tr>
<tr>
<td stylecode="Lrule " valign="top">
<paragraph> VASP-PRI (%) † <br/>
</paragraph>
</td>
<td valign="top">
<paragraph> 300 mg (24 h)<br/>600 mg (24 h) <br/>75 mg (Day 5) <br/>150 mg (Day 5) <br/>
</paragraph>
</td>
<td align="center" valign="top">
<paragraph> 73 (12)<br/>51 (20)<br/>40 (9)<br/>20 (10)<br/>
</paragraph>
</td>
<td align="center" valign="top">
<paragraph> 68 (16)<br/>48 (20)<br/>39 (14)<br/>24 (10)<br/>
</paragraph>
</td>
<td align="center" valign="top">
<paragraph> 78 (12)<br/>56 (26)<br/>50 (16)<br/>29 (11)<br/>
</paragraph>
</td>
<td align="center" stylecode="Rrule " valign="top">
<paragraph> 91 (12)<br/>85 (14)<br/>83 (13)<br/>61 (18)<br/>
</paragraph>
</td>
</tr>
<tr>
<td colspan="6" stylecode="Rrule Botrule Lrule " valign="top">
<paragraph> Values are mean (SD) <br/>*Inhibition of platelet aggregation with 5mcM ADP; larger value indicates greater platelet inhibition<br/>† Vasodilator-stimulated phosphoprotein – platelet reactivity index; smaller value indicates greater platelet inhibition<br/>
</paragraph>
</td>
</tr>
</tbody>
</table>